News

Following a pre-IND meeting with the FDA, Innocoll will conduct two multi-centered Phase III clinical trials in the US to support the planned new drug application; the first

The Gore Vibrant study is a randomized, prospective, multi-center clinical trial intended to demonstrate patency superiority in the treatment of lesions eight centimetres or longer with the Gore

Canon Staar has been renamed Staar Japan and has become a wholly owned subsidiary of Staar operating directly in the Japanese market. The transaction is expected to increase

Assuming FDA acceptance of the IND application, Neopharm intends to enter a Phase I clinical study to assess the maximum tolerated dose and dose limiting toxicity (DLT) of

Under the terms of this agreement, which has a 10-year term, Biovail will manufacture and supply once-daily extended-release tramadol hydrochloride tablets in dosage strengths of 100mg, 200mg and

The licensee has paid ZymeQuest an initial licensing fee of $2 million. In addition, the license agreement provides for the payment of royalties based on production levels of

The Phase II clinical trial is a open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily versus azathioprine (AZA),

All patients have completed their final clinical assessment. The data are being analysed, and results will be delivered in the first quarter of 2008. This Phase IIa trial

The bipolar mania submission is based on a clinical study of once-daily treatment with Seroquel, compared to placebo, with a primary endpoint of change in YMRS (Young Mania